Coronavirus Stimulus Bill, Remdesivir’s Orphan Status, Teva’s Copaxone Suit

Citeline Podcasts - A podcast by Citeline

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Pink Sheet editor and reports discuss pharma’s wins in the latest coronavirus stimulus bill, explain Gilead’s decision to pull the remdesivir orphan designation, and consider Teva’s suit to force Copaxone’s transition to regulation as a biologic.

Visit the podcast's native language site